DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy
Rationale Key biologic effects of the alpha-particle emitter Actinium-225 in comparison to the beta-particle emitter Lutetium-177 labeled somatostatin-analogue DOTATOC in vitro and in vivo were studied to evaluate the significance of γH2AX-foci formation. Methods To determine the relative biological effectiveness (RBE) between the two isotopes (as - biological consequence of different ionisation-densities along a particle-track), somatostatin expressing AR42J cells were incubated with Ac-225-DOTATOC and Lu-177-DOTATOC up to 48 h and viability was analyzed using the MTT assay. DNA double strand breaks (DSB) were quantified by immunofluorescence staining of γH2AX-foci. Cell cycle was analyzed by flow cytometry. In vivo uptake of both radiolabeled somatostatin-analogues into subcutaneously growing AR42J tumors and the number of cells displaying γH2AX-foci were measured. Therapeutic efficacy was assayed by monitoring tumor growth after treatment with activities estimated from in vitro cytotoxicity. Results Ac-225-DOTATOC resulted in ED50 values of 14 kBq/ml after 48 h, whereas Lu-177-DOTATOC displayed ED50 values of 10 MBq/ml. The number of DSB grew with increasing concentration of Ac-225-DOTATOC and similarly with Lu-177-DOTATOC when applying a factor of 700-fold higher activity compared to Ac-225. Already 24 h after incubation with 2.5–10 kBq/ml, Ac-225-DOTATOC cell-cycle studies showed up to a 60% increase in the percentage of tumor cells in G2/M phase. After 72 h an apoptotic subG1 peak was also detectable. Tumor uptake for both radio peptides at 48 h was identical (7.5%ID/g), though the overall number of cells with γH2AX-foci was higher in tumors treated with 48 kBq Ac-225-DOTATOC compared to tumors treated with 30 MBq Lu-177-DOTATOC (35% vs. 21%). Tumors with a volume of 0.34 ml reached delayed exponential tumor growth after 25 days (44 kBq Ac-225-DOTATOC) and after 21 days (34 MBq Lu-177-DOTATOC). Conclusion γH2AX-foci formation, triggered by beta- and alpha-irradiation, is an early key parameter in predicting response to internal radiotherapy.
References
[1]
Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, et al. (2012) Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 39 Suppl 1S103–112. doi: 10.1007/s00259-011-2039-y
[2]
Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24: 389–427. doi: 10.1210/er.2002-0007
[3]
McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, et al. (1998) Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25: 1341–1351. doi: 10.1007/s002590050306
[4]
Dadachova E (2010) Cancer therapy with alpha-emitters labeled peptides. Semin Nucl Med 40: 204–208. doi: 10.1053/j.semnuclmed.2010.04.002
[5]
Morgenstern A, Bruchertseifer F, Apostolidis C (2011) Targeted alpha therapy with 213Bi. Curr Radiopharm 4: 295–305. doi: 10.2174/1874471011104040295
[6]
Miederer M, Scheinberg DA, McDevitt MR (2008) Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev 60: 1371–1382. doi: 10.1016/j.addr.2008.04.009
[7]
Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, et al. (2009) Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res 69: 8941–8948. doi: 10.1158/0008-5472.can-09-1828
[8]
Essler M, Gartner FC, Neff F, Blechert B, Senekowitsch-Schmidtke R, et al. (2012) Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging 39: 602–612. doi: 10.1007/s00259-011-2023-6
[9]
Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, et al. (2008) Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res 14: 3555–3561. doi: 10.1158/1078-0432.ccr-07-4647
[10]
Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, et al. (2007) Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res 67: 1950–1958. doi: 10.1158/0008-5472.can-06-3569
[11]
Roscher M, Hormann I, Leib O, Marx S, Moreno J, et al. (2013) Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells. Oncotarget 4: 218–230.
[12]
Chu J, Ji H, Lu M, Li Z, Qiao X, et al. (2013) Proteomic analysis of apoptotic and oncotic pancreatic acinar AR42J cells treated with caerulein. Mol Cell Biochem 382: 1–17. doi: 10.1007/s11010-013-1603-0
[13]
Apostolidis C, Molinet R, Rasmussen G, Morgenstern A (2005) Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 77: 6288–6291. doi: 10.1021/ac0580114
[14]
Olive PL, Banath JP (2006) The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 1: 23–29. doi: 10.1038/nprot.2006.5
[15]
Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, et al. (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35: 206–221. doi: 10.1002/(sici)1098-2280(2000)35:3<206::aid-em8>3.0.co;2-j
[16]
Olive PL, Banath JP, Durand RE (1990) Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the “comet” assay. Radiat Res 122: 86–94. doi: 10.2307/3577587
[17]
Thompson LH (2012) Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res 751: 158–246. doi: 10.1016/j.mrrev.2012.06.002
[18]
Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421: 499–506. doi: 10.1038/nature01368
[19]
Derheimer FA, Kastan MB (2010) Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett 584: 3675–3681. doi: 10.1016/j.febslet.2010.05.031
[20]
Kinner A, Wu W, Staudt C, Iliakis G (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36: 5678–5694. doi: 10.1093/nar/gkn550
[21]
White JS, Yue N, Hu J, Bakkenist CJ (2011) The ATM kinase signaling induced by the low-energy beta-particles emitted by (33)P is essential for the suppression of chromosome aberrations and is greater than that induced by the energetic beta-particles emitted by (32)P. Mutat Res 708: 28–36. doi: 10.1016/j.mrfmmm.2011.01.005
[22]
Meyer B, Voss KO, Tobias F, Jakob B, Durante M, et al. (2013) Clustered DNA damage induces pan-nuclear H2AX phosphorylation mediated by ATM and DNA-PK. Nucleic Acids Res 41: 6109–6118. doi: 10.1093/nar/gkt304
[23]
Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, et al. (2013) gamma-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). Clin Cancer Res 19: 721–730. doi: 10.1158/1078-0432.ccr-12-2529
[24]
Staaf E, Brehwens K, Haghdoost S, Czub J, Wojcik A (2012) Gamma-H2AX foci in cells exposed to a mixed beam of X-rays and alpha particles. Genome Integr 3: 8. doi: 10.1186/2041-9414-3-8
[25]
Nayak TK, Norenberg JP, Anderson TL, Prossnitz ER, Stabin MG, et al. (2007) Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol 34: 185–193. doi: 10.1016/j.nucmedbio.2006.11.006
[26]
Behr TM, Behe M, Stabin MG, Wehrmann E, Apostolidis C, et al. (1999) High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17–1A Fab’ fragments in a human colonic cancer model. Cancer Res 59: 2635–2643.
[27]
Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J (2013) Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm 6: 20–27. doi: 10.2174/1874471011306010004
[28]
Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, et al. (2010) MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 51: 311–328. doi: 10.2967/jnumed.108.058651
[29]
McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, et al. (2001) Tumor therapy with targeted atomic nanogenerators. Science 294: 1537–1540. doi: 10.1126/science.1064126
[30]
Xue D, Zhang W, Liang T, Zhao S, Sun B, et al. (2009) Effects of arsenic trioxide on the cerulein-induced AR42J cells and its gene regulation. Pancreas 38: e183–189. doi: 10.1097/mpa.0b013e3181b65dec
[31]
Haro KJ, Scott AC, Scheinberg DA (2012) Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood 120: 2087–2097. doi: 10.1182/blood-2012-01-404509
